Literature DB >> 16697090

Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.

Melissa M Kahl-McDonagh1, Philip H Elzer, Sue D Hagius, Joel V Walker, Quinesha L Perry, Christopher M Seabury, Andreas B den Hartigh, Renee M Tsolis, L Garry Adams, Donald S Davis, Thomas A Ficht.   

Abstract

Pregnant goats were employed to assess unmarked deletion mutant vaccine candidates BMDeltaasp24, BMDeltacydBA, and BMDeltavirB2, as the target host species naturally infected with Brucella melitensis. Goats were assessed for the degree of pathology associated with the vaccine strains as well as the protective immunity afforded by each strain against abortion and infection after challenge with wild-type Brucella melitensis 16M. Both BMDeltaasp24 and BMDeltavirB2 were considered safe vaccine candidates in the pregnant goat model because they did not cause abortion or colonize fetal tissues. BMDeltaasp24 was isolated from the maternal tissues only, indicating a slower rate of clearance of the vaccine strain than for BMDeltavirB2, which was not isolated from any maternal or fetal tissues. Both strains were protective against abortion and against infection in the majority of pregnant goats, although BMDeltaasp24 was more efficacious than BMDeltavirB2 against challenge infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697090     DOI: 10.1016/j.vaccine.2006.04.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; Y Fan; M M Kahl-McDonagh; T A Ficht
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

2.  Different roles of the two high-oxygen-affinity terminal oxidases of Brucella suis: Cytochrome c oxidase, but not ubiquinol oxidase, is required for persistence in mice.

Authors:  Maria Pilar Jiménez de Bagüés; Séverine Loisel-Meyer; Jean-Pierre Liautard; Véronique Jubier-Maurin
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

3.  Mechanism of Asp24 upregulation in Brucella abortus rough mutant with a disrupted O-antigen export system and effect of Asp24 in bacterial intracellular survival.

Authors:  Mingxing Tian; Jing Qu; Xiangan Han; Chan Ding; Shaohui Wang; Daxin Peng; Shengqing Yu
Journal:  Infect Immun       Date:  2014-04-21       Impact factor: 3.441

4.  Characterization and protective property of Brucella abortus cydC and looP mutants.

Authors:  Quang Lam Truong; Youngjae Cho; Abhijit Kashinath Barate; Suk Kim; Tae-Wook Hahn
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

5.  Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; M M Kahl-McDonagh; T A Ficht
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

6.  Inactivation of the type IV secretion system reduces the Th1 polarization of the immune response to Brucella abortus infection.

Authors:  Hortensia García Rolán; Renée M Tsolis
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

Review 7.  Survival of the fittest: how Brucella strains adapt to their intracellular niche in the host.

Authors:  R Martin Roop; Jennifer M Gaines; Eric S Anderson; Clayton C Caswell; Daniel W Martin
Journal:  Med Microbiol Immunol       Date:  2009-09-22       Impact factor: 3.402

Review 8.  Brucellosis: the case for live, attenuated vaccines.

Authors:  Thomas A Ficht; Melissa M Kahl-McDonagh; Angela M Arenas-Gamboa; Allison C Rice-Ficht
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

9.  Large scale immune profiling of infected humans and goats reveals differential recognition of Brucella melitensis antigens.

Authors:  Li Liang; Diana Leng; Chad Burk; Rie Nakajima-Sasaki; Matthew A Kayala; Vidya L Atluri; Jozelyn Pablo; Berkay Unal; Thomas A Ficht; Eduardo Gotuzzo; Mayuko Saito; W John W Morrow; Xiaowu Liang; Pierre Baldi; Robert H Gilman; Joseph M Vinetz; Renée M Tsolis; Philip L Felgner
Journal:  PLoS Negl Trop Dis       Date:  2010-05-04

10.  VirB12 is a serological marker of Brucella infection in experimental and natural hosts.

Authors:  Hortensia G Rolán; Andreas B den Hartigh; Melissa Kahl-McDonagh; Thomas Ficht; L Garry Adams; Renée M Tsolis
Journal:  Clin Vaccine Immunol       Date:  2007-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.